Publications

Detailed Information

Therapeutics in the Treatment of COVID-19 for Children and Adolescents

DC Field Value Language
dc.contributor.authorChoi, Soo-Han-
dc.contributor.authorChoi, Jae Hong-
dc.contributor.authorYun, Ki Wook-
dc.date.accessioned2022-09-30T05:54:19Z-
dc.date.available2022-09-30T05:54:19Z-
dc.date.created2022-08-18-
dc.date.issued2022-04-
dc.identifier.citationPediatric Infection and Vaccine, Vol.29 No.1, pp.1-15-
dc.identifier.issn2384-1079-
dc.identifier.urihttps://hdl.handle.net/10371/184993-
dc.description.abstract© 2022 The Korean Society of Pediatric Infectious Diseases.Coronavirus disease 2019 (COVID-19) presents as a mild-to-moderate respiratory illness in most children. However, a small proportion of children with COVID-19 develop severe or critical illnesses. Although pediatric clinical trials for the treatment of COVID-19 are sparse, some drugs are available for children and adolescents with severe COVID-19. This review summarizes clinical data focusing on antiviral agents and immunomodulators for use in treating COVID-19. In addition, current recommendations for therapeutics for children and adolescents with COVID-19 are discussed.-
dc.language영어-
dc.publisherThe Korean Society of Pediatric Infectious Diseases-
dc.titleTherapeutics in the Treatment of COVID-19 for Children and Adolescents-
dc.typeArticle-
dc.identifier.doi10.14776/piv.2022.29.e1-
dc.citation.journaltitlePediatric Infection and Vaccine-
dc.identifier.scopusid2-s2.0-85131331853-
dc.citation.endpage15-
dc.citation.number1-
dc.citation.startpage1-
dc.citation.volume29-
dc.identifier.kciidART002839444-
dc.description.isOpenAccessN-
dc.contributor.affiliatedAuthorYun, Ki Wook-
dc.type.docTypeReview-
dc.description.journalClass1-
Appears in Collections:
Files in This Item:
There are no files associated with this item.

Altmetrics

Item View & Download Count

  • mendeley

Items in S-Space are protected by copyright, with all rights reserved, unless otherwise indicated.

Share